BRCA mutations: is everything said?

BackgroundMutations in the BRCA1 and BRCA2 genes constitute a risk factor for breast cancer development. BRCA mutation research has been an active field since the discovery of the genes, and new mutations in both genes are constantly described and classified according to several systems.AimWe intend to provide an overview of the current state of BRCA1 and BRCA2 mutation description and classification. We wanted to know whether there was a trend towards a more frequently described mutation type and what the proportion of pathogenic mutations was.ResultsWe found that, although new mutations are described each year as reflected in current database records, very few of them are reported in papers. Classification systems are highly heterogeneous and a consensus among them is still under development. Regarding their function, a large number of mutations are yet to be analyzed, a very complex task, due to the great number of possible variations and their diverse effect in the BRCA gene functions. After individual analysis, many variants of unknown significance turn out to be pathogenic, and many can disrupt interactions with other proteins involved in mechanisms such as DNA damage repair pathways. Recent data suggest that looking for mutation patterns or combinations would shed a wider light on BRCA-derived cancer susceptibility in the upcoming years.

[1]  Ricardo Villamarín-Salomón,et al.  ClinVar: public archive of interpretations of clinically relevant variants , 2015, Nucleic Acids Res..

[2]  J. Glover,et al.  Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays. , 2010, Cancer research.

[3]  C. Deng,et al.  Genetic Interactions between Brca1 and Gadd45a in Centrosome Duplication, Genetic Stability, and Neural Tube Closure* , 2004, Journal of Biological Chemistry.

[4]  G. Lenoir,et al.  A 1-kb Alu-mediated germ-line deletion removing BRCA1 exon 17. , 1997, Cancer research.

[5]  Y. Miki,et al.  BRCA1 gene: function and deficiency , 2018, International Journal of Clinical Oncology.

[6]  A Gulino,et al.  BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  S. Lees-Miller,et al.  DNA damage-induced activation of ATM and ATM-dependent signaling pathways. , 2004, DNA repair.

[8]  Michael T. Zimmermann,et al.  Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas , 2018, Cell reports.

[9]  Fergus J Couch,et al.  A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. , 2007, American journal of human genetics.

[10]  Nazneen Rahman,et al.  Breast-cancer risk in families with mutations in PALB2. , 2014, The New England journal of medicine.

[11]  F. Couch,et al.  Classification of missense substitutions in the BRCA genes: A database dedicated to Ex‐UVs , 2012, Human mutation.

[12]  T. Frebourg,et al.  Exonic Splicing Mutations Are More Prevalent than Currently Estimated and Can Be Predicted by Using In Silico Tools , 2016, PLoS genetics.

[13]  A. Hollestelle,et al.  BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. , 2006, Cancer research.

[14]  S. Antonarakis.  Recommendations for a nomenclature system for human gene mutations , 1998 .

[15]  M. King,et al.  Population genetics of BRCA1 and BRCA2. , 1997, American journal of human genetics.

[16]  G. Lenoir,et al.  Differential expression and subcellular localization of murine BRCA1 and BRCA1‐δ11 isoforms in murine and human cell lines , 2000 .

[17]  S. Kean.  Breast cancer. The 'other' breast cancer genes. , 2014, Science.

[18]  S. Mazoyer.  Genomic rearrangements in the BRCA1 and BRCA2 genes , 2005, Human mutation.

[19]  K. Frazer,et al.  Human genetic variation and its contribution to complex traits , 2009, Nature Reviews Genetics.

[20]  Roberto Giugliani,et al.  Genomic rearrangements in BRCA1 and BRCA2: A literature review , 2009, Genetics and molecular biology.

[21]  R. Cotton.  Recommendations of the 2006 Human Variome Project meeting , 2007, Nature Genetics.

[22]  Sue Healey,et al.  ENIGMA—Evidence‐based network for the interpretation of germline mutant alleles: An international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes , 2012, Human mutation.

[23]  F. Couch,et al.  BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  Georgia Chenevix-Trench,et al.  An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA) , 2007, Breast Cancer Research.

[25]  Lara E Sucheston-Campbell,et al.  Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Annette Lee,et al.  Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations , 2018, Human mutation.

[27]  C. Doss,et al.  An Integrated in Silico Approach to Analyze the Involvement of Single Amino Acid Polymorphisms in FANCD1/BRCA2-PALB2 and FANCD1/BRCA2-RAD51 Complex , 2014, Cell Biochemistry and Biophysics.

[28]  S. Antonarakis,et al.  Nomenclature for the description of human sequence variations , 2001, Human Genetics.

[29]  David Haussler,et al.  Consistency of BRCA1 and BRCA2 Variant Classifications Among Clinical Diagnostic Laboratories , 2017, JCO precision oncology.

[30]  T. Frebourg,et al.  Functional Analysis of a Large set of BRCA2 exon 7 Variants Highlights the Predictive Value of Hexamer Scores in Detecting Alterations of Exonic Splicing Regulatory Elements , 2013, Human mutation.

[31]  P. Mehdipour,et al.  A Comprehensive Focus on Global Spectrum of BRCA1 and BRCA2 Mutations in Breast Cancer , 2013, BioMed research international.

[32]  I. Screpanti,et al.  Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families , 2006, Breast Cancer Research and Treatment.

[33]  K. Kyriacou,et al.  BRCA1 and Its Network of Interacting Partners , 2012, Biology.

[34]  T. Hansen,et al.  Functional characterization of BRCA1 gene variants by mini-gene splicing assay , 2014, European Journal of Human Genetics.

[35]  P. Chappuis,et al.  Twenty-three novel BRCA1 and BRCA2 sequence variations identified in a cohort of Swiss breast and ovarian cancer families. , 2006, Cancer genetics and cytogenetics.

[36]  F. Ruíz-Espejo,et al.  Mutational analysis of RAD51C and RAD51D genes in hereditary breast and ovarian cancer families from Murcia (southeastern Spain). , 2018, European journal of medical genetics.

[37]  Y. Wang,et al.  The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin. , 2016, Cancer research.

[38]  M. Stratton,et al.  COSMIC 2005 , 2006, British Journal of Cancer.

[39]  Acmg Board Of Directors.  Laboratory and clinical genomic data sharing is crucial to improving genetic health care: a position statement of the American College of Medical Genetics and Genomics , 2017, Genetics in Medicine.

[40]  A. Børresen-Dale,et al.  Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study , 2010, Human mutation.

[41]  Olufunmilayo I. Olopade,et al.  Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations , 2007, Nature Reviews Cancer.

[42]  F. Couch,et al.  Mutations and Polymorphisms in the familial early‐onset breast cancer (BRCA1) gene , 1996, Human mutation.